Cor Integrilin Higher Dosing Data First Quarter FDA Filing Expected
Executive Summary
Cor Therapeutics expects to file study data with FDA during the first quarter for a change in the Integrilin (eptifibatide) dosing regimen for patients undergoing coronary stent procedures.
You may also be interested in...
Cor Integrilin
FDA approves supplemental indication for eptifibatide June 8 for patients with acute coronary syndrome, including those undergoing percutaneous coronary intervention. Approval is based on data from Cor's ESPRIT trial (1"The Pink Sheet" Jan. 15, p. 7)
Cor Integrilin
FDA approves supplemental indication for eptifibatide June 8 for patients with acute coronary syndrome, including those undergoing percutaneous coronary intervention. Approval is based on data from Cor's ESPRIT trial (1"The Pink Sheet" Jan. 15, p. 7)
Cor/Schering Integrilin Revenue Recovery Projected After Label Change
Cor Therapeutics expects Integrilin efficacy data and the co-promotional deal with Genentech will help the company recover from the recent inventory drawdown of the peptide glycoprotein IIb/IIIa receptor antagonist.